Professor Liang Xu is engaged in the teaching, scientific research and innovative manufacturing of traditional Chinese medicine resources, research and development of new drugs for traditional Chinese medicine health care products, cultivation of traditional Chinese medicine and transgenic engineering of traditional Chinese medicine. He has presided over or participated in the national key scientific and technological projects in the Ninth Five-Year Plan and the Tenth Five-Year Plan, supported by the National Natural Science Foundation, the research on the expression of T cell receptor Vβ gene in LAK cells induced by anti-CD3 monoclonal antibody, the identification and cloning of liver cancer antigen TCRνβ gene subfamily by McAb*** stimulation screening, and the research on GAP, the raw material of Artemisia annua anti-malaria, anti-cancer and anti-AIDS compound drug. National key scientific and technological project "Research on GAP planting of five Chinese herbal medicines such as Amomum villosum", Tenth Five-year national key scientific and technological project "Research on GAP base construction and quality standards of five Chinese herbal medicines such as Alpinia officinarum", "Study on breeding of fine varieties of Artemisia annua and application and popularization of its high-yield cultivation techniques", and key project of national science and technology basic platform "Formulation and demonstration of description standards and norms of Pogostemon cablin germplasm resources" (Ministry of Science and Technology); As well as provincial and ministerial scientific research projects, such as the construction of South China traditional Chinese medicine germplasm resources bank, the development of innovative special liniment for treating major burns and scalds without skin grafting and scar, the extraction of effective active ingredients from Chinese herbal medicines for whitening, softening and removing spots and the research on their preparation products, the Guangdong Science and Technology Plan project, the construction of South China traditional Chinese medicine germplasm resources bank, the screening of excellent germplasm of southern medicine Pogostemon cablin and the research on high-yield new technology, and the standardized cultivation of Acacia/Desmodium styracifolium in Guangzhou. More than 20 scientific research projects have been studied, including the construction of demonstration base, the research on GAP planting of raw materials such as Livzon Group Xueshuantong injection, the construction of GAP planting base of raw materials such as Wang Laoji and Gangmei, the construction of honeysuckle planting base as the main raw material of Deng Lao herbal tea, the research on GAP planting management technology, and the research on key technologies of standardized planting and industrialization demonstration of Lingnan traditional Chinese medicine mulberry. At the same time, he participated in the proposition and validation of the national licensed pharmacist qualification examination organized by the state, the revision and certification of national laws and regulations such as the national standards for inspection and evaluation of GAP certification of Chinese herbal medicines and the management measures for GAP certification. Responsible for the overall planning and design of traditional Chinese medicine eco-tourism and health care medicine Expo parks in many provinces and cities (such as the construction of "International Chinese Medicine Port" and "Medicine Expo Park" in Qingyuan City, Nanxiong City, Guangdong Province and Liuzhou City, Guangxi Province) and the specific implementation and construction of on-site guidance. Invited and appointed by the US Food and Drug Administration, Professor Liang Xu has successively obtained national GAP certification for many large Chinese medicine manufacturers and their medicinal materials planting bases in Tianjin Tasly Pharmaceutical Group Co., Ltd., Shaanxi Tasly Botanical Pharmaceutical Company, Beijing Tongrentang Pharmaceutical Group Co., Ltd., Shanxi Lingchuan Tongrentang Dangshen Pharmaceutical Co., Ltd., Henan Zhangzhongjing Pharmaceutical Group Co., Ltd., Henan Wanxi Pharmaceutical Co., Ltd., Guangyao Zhong Yi Pharmaceutical Company Astragalus Production Base, Inner Mongolia Zhong Yi Astragalus Pharmaceutical Co., Ltd. and other provinces and cities. It enjoys high prestige and academic influence in the fields of advanced personnel training, popularization of scientific knowledge, GAP research, GAP certification, research and development of new Chinese medicine health care products, and research on genetically modified engineering. Among them, Professor Xu participated in the "Ninth Five-Year Plan" national key scientific and technological research project "Study on standardized cultivation of five Chinese herbal medicines such as Amomum villosum" from 2000 to 2003 and won the third prize of Guangdong Science and Technology Progress in 2003; From 2004 to 2006, the project "Application and Popularization of High-yield Cultivation Techniques of Artemisia annua" hosted by Meizhou City won the third prize of Meizhou Municipal People's Government for scientific and technological progress, and the research and development and application of artemisinin compound, a drug-resistant falciparum malaria control drug of Artemisia annua, won the second prize of China and the State Council in 2005 for national scientific and technological progress. In 2006, Professor Liang Xu was elected to the National Higher Education of the Ministry of Education.